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Abstract 
GENE DISCOVERY IN DEVELOPMENTAL NEUROPSYCHIATRIC DISORDERS: 
CLUES FROM CHROMOSOMAL REARRANGEMENTS. Thomas Fernandez1, 
Thomas Morgan2, Nicole Davis1, Ami Klin1, and Matthew W. State1,2,3. 'Child Study 
Center, "Department of Genetics, and Yale Center for Human Genetics and Genomics, 
Yale University, School of Medicine, New Haven, CT. 
The molecular characterization of rare affected individuals presenting with chromosomal 
abnormalities has made recent important contributions to disease gene identification in 
developmental disorders and autism. Here we review the success of this approach 
compared to more traditional approaches toward disease gene identification for complex 
developmental neuropsychiatric disorders. We report on cases of children affected by 
autism and pervasive developmental disorder (PDD) with different balanced 
chromosomal translocations. By using fluorescent in situ hybridization (FISH) to fine- 
map the breakpoints of these chromosomal rearrangements, we discovered the physical 
disruption of one gene transcript (Contactin4, CNTN4) in a boy with PDD and a 
phenotype consistent with 3p deletion syndrome. Our results demonstrate the association 
of CNTN4 disruption with the 3p deletion syndrome phenotype, strongly suggest a causal 
relationship, and point to an important role for CNTN4 in normal and abnormal CNS 
development. We subsequently screened a cohort of patients (N=97) with autism and 
autism spectrum disorders (ASDs) and normal karyotypes, along with control subjects 
(N=234), for mutations in coding regions of this gene. One missense mutation was 
identified in a multiplex ASD family and not found in controls, although this mutation 
did not completely co-segregate with affected status. Finally, by mapping the breakpoints 
of an inherited translocation in three autistic siblings, we identified an interesting 
candidate gene for autism susceptibility on chromosome 11 that warrants additional 
study. 
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INTRODUCTION 
Evidence for the heritable nature of developmental neuropsychiatric disorders such as 
autism has been known for several decades. Twin and family studies from the 1970s have 
clearly established the importance of genetic factors in autism and autism spectrum 
disorders (ASDs), with monozygotic twins showing concordance rates of 40-60% and 70- 
90%, respectively, compared with rates of 0-25% in dizygotic twins (1-3). The sibling 
recurrence risk for autism is estimated at 2-6%, which is 50-100 times greater than the 
population prevalence of 0.04-0.1% (3-5). With an estimated heritability of 
approximately 90%, the rate by which the incidence of autism and ASDs drops among 
successive generations of relatives suggests that disease susceptibility arises from a 
complex mode of inheritance, involving the combined effects of multiple, possibly 
interacting genes (6, 7). 
Over the last decade, different approaches have been utilized in an attempt to identify 
genes involved in the etiology of complex developmental disorders. The basic principles 
behind these strategies are briefly reviewed below. 
Traditional approaches to disease gene identification 
The two most widely employed approaches to disease gene identification, or 
mapping, are linkage and association studies. Linkage is based on identifying markers 
that co-segregate with the disease within families. This approach classically uses 
multigenerational pedigrees containing several affected individuals in which it is possible 
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to infer the mode of inheritance of the disease locus and specify the relevant parameters. 
In genetically complex disorders such as autism, the mode of inheritance is generally 
unknown and large affected pedigrees are unavailable. Therefore, alternative “model 
free”, or non-parametric, linkage methods are used that do not require specification of an 
inheritance model but instead rely on assessing allele sharing between two or more 
affected individuals within multiple nuclear families. The goal is to identify genetic 
markers at which affected pairs share alleles more often than expected by chance, as such 
markers may be linked to a susceptibility gene. Although these non-parametric linkage 
methods are robust, they have relatively low power to detect genes of small effect; in this 
scenario, association studies are more powerful. 
Association strategies are based on identifying alleles that occur at significantly 
different frequencies in samples of affected versus control individuals. Case-control 
studies utilize unrelated controls, and careful matching is required to avoid false positive 
results due to cases and controls being drawn from different gene pools. Family-based 
association designs, such as the transmission disequilibrium test (TDT), overcome this 
potential difficulty by using the frequencies of parental alleles that are not transmitted to 
affected offspring as internal controls (8). Association of a particular allele with a disease 
can occur if the allele is implicated in the etiology of the disease, or if it is in linkage 
disequilibrium with the susceptibility locus. Since association is usually only detectable if 
the allele is very close to or within the susceptibility gene, this approach is predominantly 
used to test polymorphisms within known candidate genes, or as a tool for fine mapping a 
region of interest identified by linkage studies (9). 
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Outcome of traditional approaches in psychiatric genetics 
Overall, the field of psychiatric genetics has had few successes in attempts to find 
relevant genes through standard linkage analysis. While several genome-wide linkage 
studies of autism and ASDs have suggested multiple intervals that may contain relevant 
loci, this approach has not yet led to the identification of a specific transcript conferring 
disease risk. The most recent and largest of ten independent genome-wide scans of 
patients with ASDs found no statistically significant evidence for linkage, but showed 
‘suggestive’ evidence for linkage on chromosomes 17q, 5p, 1 lp, 4q, and 8q, with 
multipoint maximum LOD scores between 1.60-2.83 (10). It is likely that a combination 
of genetic heterogeneity, clinical heterogeneity, an uncertain mode of inheritance, and the 
interaction of multiple genes that increase susceptibility to autism, rather than directly 
cause it, have hindered efforts at disease gene identification. As a result of these factors, 
the correlation between disease status and any given DNA marker allele in a genome¬ 
wide linkage study tends to be relatively weak, and the implicated regions, or linkage 
peaks, typically encompass a large and often unmanageable number of positional 
candidate genes, the vast majority of which are unrelated to the disorder. 
N. 
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An alternate approach to disease gene identification 
Due to the difficulties with traditional approaches for disease gene identification 
outlined above, alternative approaches are warranted. One such strategy for candidate 
gene discovery relies on the characterization of rare affected individuals who present with 
chromosomal abnormalities (“genetic outliers”). Mapping the breakpoints in 
chromosomal deletions and translocations associated with a disorder can be particularly 
relevant in the attempt to pinpoint candidate gene loci, as this may clearly identify a 
disrupted gene or genes. This approach has been used successfully in helping to identify 
the genes for multiple disorders, including Duchenne muscular dystrophy, familial 
Alzheimer’s disease (11) and a host of mental retardation syndromes (12). 
In psychiatry, this approach of studying genetic outliers has recently led to the 
identification of Neuroligin 4 (NLGN4) as one of the first transcripts corresponding to 
“idiopathic autism”. In this case, cytogenetic studies found X-chromosome deletions in 
three autistic patients (13). This led to screening of a candidate interval, resulting in the 
demonstration of a functional mutation that segregated with ASDs in a European family 
(14). Two subsequent independent human genetic studies have confirmed these initial 
findings for NLGN4 (15, 16) and another has demonstrated the functional relevance of 
the identified NLGN4 mutations (17). 
These recent results with autism demonstrate the opportunities presented by the study 
of unusual patients with cytogenetic abnormalities. Despite this opportunity, 
chromosomal anomalies remain understudied in developmental disorders such as ASDs 
(18). While such efforts are most likely to identify genes of major effect that are of 
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consequence for only a small sub-group of individuals with ASDs, they promise to yield 
important insights into physiologic pathways and genetic mechanisms involved in more 
common forms of these disorders. 
Statement of purpose and hypothesis 
Using molecular genetic techniques to investigate and characterize the 
breakpoints of chromosomal abnormalities in individual patients with developmental 
delay and ASDs will identify interesting candidate genes involved in their pathology. 
Based on these findings, screening genomic DNA for sequence variations in the 
identified gene(s) in a larger cohort of affected and control subjects without known 
cytogenetic abnormalities will suggest whether such regions may be involved in only rare 
or more common cases of these disorders. The identification of such mutations in even a 
small number of cases may provide insights into underlying disease mechanisms. 
MATERIALS AND METHODS 
Analysis of individual patients with known chromosomal abnormalities 
Patient assessment 
Molecular analysis of four patients with ASDs and known cytogenetic 
abnormalities was completed using the methods described below. These patients were 
obtained through referral to the Yale Child Study Center (YCSC) and the Yale Outpatient 
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Genetics Clinic. Clinical assessment of these patients was performed by members of the 
faculty and staff of YCSC and the Department of Genetics. Physical examinations, 
medical and family histories, and scores on standardized ASD rating scales (described 
below) were obtained for each patient. 
Karyotype analysis 
Standard chromosome preparations from all participants were made from PHA- 
stimulated peripheral blood lymphocytes. Conventional G-banded chromosome analyses 
were performed on metaphase cells with a minimum resolution level of 550 bands. 
Fluorescence in situ hybridization analysis 
In order to fine map chromosomal rearrangements detected by cytogenetics, 
fluorescent in situ hybridizations (FISH) of metaphase nuclei were carried out as 
previously described (19). Bacterial Artificial Chromosome (BAC) clones corresponding 
to the regions of interest identified on G-banding analysis were identified using the 
UCSC Human Genome Browser at http://genome.ucsc.edu/ (July 2003 freeze) and 
obtained from an RPCI-11 (Roswell Park Cancer Institute) BAC library. These BAC 
clones were cultured, the human DNA inserts were extracted, and then fluorescently 
labeled by nick translation. Labeled BAC DNA was ethanol precipitated along with Cotl 
DNA to block repetitive sequences. Each clone was then used as a probe and hybridized 
to metaphase spreads consisting of the patient's lymphocytes. Following hybridization, 
the nuclei were counterstained with DAPI to distinguish nuclei from background and 
observed under multi-wavelength fluorescent microscopy. 
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Array-based copy number analysis 
The GeneChip Mapping 100K Set (Affymetrix, Inc., Santa Clara, CA) was used 
to examine the chromosomes of several patients in this study. The 100K Set is composed 
of two arrays, each with greater than 50,000 SNPs with 8.5 kb median physical distance 
and 23.6 kb average distance between SNPs. SNP GeneChip assay was performed 
according to the manufacturer’s manual. Total genomic DNA (250ng) was digested with 
restriction enzymes Xbal and Hindlll (New England Biolabs) for 2 hours at 37°C to 
reduce the complexity of the genome and then, ligated to an adapter that recognizes the 
cohesive four base pair (bp) overhangs using T4 DNA ligase at 16°C for 2.5 h. 
Subsequently, adapter ligated DNA fragments were amplified using a generic primer that 
recognizes the adapter sequence. The PCR product sizes ranged from 250 to 2,000 bp. A 
total of 40 pg of purified PCR products were fragmented with Dnasel. Fragmented PCR 
products were biotin- labeled and hybridized to GeneChip" Human Mapping 50K Array 
Xba240 and GeneChip" Human Mapping 50K Array Hind 240 for 16 h at 45 °C in an 
Affymetrix GeneChip Hybridization oven. After hybridization, the arrays were washed, 
stained, and scanned using an Affymetrix Fluidics Station F450, and images were 
obtained by using Affymetrix GeneChip scanner 3000. We analyzed cell intensity data 
from the Affymetrix®’ GeneChip® Human Mapping 100K Set using GeneChip DNA 
Analysis Software Version 3.0.2.8 (GDAS). We then used the Affymetrix ® GeneChip" 
Chromosome Copy Number Tool (CCNT) to search genome-wide chromosomal gains 
and looses at high resolution. This tool uses a reference set of >110 ethnically diverse 
normal individuals to compare with patient samples by generating averaged p-value. 
V. 
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Thresholds for copy number gain and loss (<1.4 regarded as deletion and >2.8 considered 
as gain) is detected by using two known samples with deletion and amplification. SNP 
annotations were obtained from NetAffx™ Analysis Center. 
Candidate gene identification 
After narrowing the breakpoints to the smallest region possible using FISH with 
labelled BAC probes, known genes, full length mRNAs, and spliced expressed sequence 
tags (ESTs) in the breakpoint regions were surveyed using the UCSC Human Genome 
Browser at http://genome.ucsc.edu/ (July 2003 freeze). 
Screening candidate genes in a larger population of affected patients 
Patient recruitment 
Based on the findings from cytogenetic analyses of individual patients with 
ASDs, reported here, a candidate gene was screened for mutations in a cohort of ASD 
patients without known cytogenetic abnormalities. Clinical data and DNA were obtained 
from the Autism Genetics Research Exchange (AGRE, http://www.agre.org), a DNA 
repository and family registry, housing a publicly available database of genotypic and 
extensively characterized phenotypic information. AGRE was founded by the Cure 
Autism Now Foundation (http://www.canfoundation.org) and is now supported by the 
National Institute of Mental Health (NIMH) as part of the NIMH genetics initiative. 
Families are recruited through a variety of methods (e.g. physician referral, website 
contact, and family meetings and seminars). They are ascertained on the basis that at least 

9 
two family members met criteria for a diagnosis of an ASD - autism, Asperger’s 
syndrome, or pervasive developmental disorder (PDD). To date, there are a total of 540 
AGRE families available for distribution, 490 of which are multiplex. 
AGREpopulation assessment 
The diagnosis of autism has been made using the standard Autism Diagnostic 
Interview-Revised (ADI-R) algorithm (20), with further phenotypic characterization 
using the Autism Diagnostic Observational Schedule-Generic (ADOS-G) (21), Vineland 
Adaptive Behavior Scale (22), and other cognitive tests. In addition to the diagnosis of 
autistic disorder, AGRE provides two other diagnostic classifications (‘Not Quite 
Autism’ and ‘Broad Spectrum’) to characterize those individuals on the broader autism 
spectrum who do not meet full ADI-R criteria for autism. All ADI and ADOS raters 
undergo ongoing reliability checks to prevent any drift in diagnosis (20, 21). In addition, 
pediatric neurologists assess photographic dysmorphology, perform physical and 
neurological examinations, and collect medical and family history. Probands with 
possible non-idiopathic autism resulting from perinatal trauma, from an identified genetic 
syndrome (e.g., fragile X syndrome), or from other medical causes are noted, although 
this represents only a small percentage of cases (23); these probands were excluded from 
the current study. 
ADI-R 
Diagnosis of autism is established by the well-validated Autism Diagnostic 
Interview Revised (ADI-R) diagnostic algorithm (20). The ADI-R is currently the gold 
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standard for research diagnosis and is based on the classifications of the International 
Statistical Classification of Diseases and Related Health Problems, 10th revision (24) as 
well as the Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV) 
(25). The interview contains 111 items and focuses on behaviors in three content areas: 
(1) quality of social interaction, (e.g., emotional sharing, offering and seeking comfort, 
social smiling and responding to other children); (2) communication and language (e.g. 
stereotyped utterances, pronoun reversal, social usage of language); and (3) repetitive, 
restricted, and stereotyped interests and behavior (e.g. unusual preoccupations, hand and 
finger mannerisms, unusual sensory interests). Responses are scored by the clinician 
based on the caregiver's description of the child's behavior. To meet criteria for autism, a 
child must meet criteria in each of the three content areas as well as exhibit some 
abnormality in at least one content area by 36 months of age. The cutoff total score for 
the communication and language content area is 8 for verbal subjects and 7 for nonverbal 
subjects. For all subjects, the cutoff for the social interaction content area is 10, and the 
cutoff for restricted and repetitive behaviors is 3. The instrument has been shown to be 
reliable and to successfully differentiate young children with autism from those with 
mental retardation and language impairments. 
ADOS-G 
The Autism Diagnostic Observation Schedule- Generic (ADOS-G) is a semi- 
structured assessment of communication, social interaction and play or imaginative use of 
materials for individuals suspected of having autism or other pervasive developmental 
disorders (PDD) (21). It is a combination of two earlier instruments: the Autism 
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Diagnostic Observation Schedule (ADOS) (26), a schedule intended for adults and 
children with language skills at a minimum of the three-year-old level, and the Pre- 
Linguistic Autism Diagnostic Observation Scale (PL-ADOS) (27), a schedule intended 
for children with limited or no language, as well as additional items developed for 
verbally fluent, high-functioning adolescents and adults. The ADOS-G consists of four 
modules, each of which is appropriate for children and adults of differing developmental 
and language levels, ranging from no expressive or receptive language to verbally fluent 
adults. 
The ADOS-G consists of standard activities that allow the examiner to observe 
the occurrence or non-occurrence of behaviors that have been identified as important to 
the diagnosis of autism and other pervasive developmental disorders across 
developmental levels and chronological ages. Overall ratings can then be used to 
formulate a diagnosis through the use of a diagnostic algorithm for each module. For 
purposes of diagnosis, use of this instrument should be accompanied by information from 
other sources, particularly a detailed history from parents whenever possible (20). 
DNA mutation detection 
One relatively new method used in this study to screen gene sequences rapidly for 
the presence of sequence variations is denaturing high-performance liquid 
chromatography (dHPLC). Initially described by Oefner and colleagues (28, 29), dHPLC 
has become a reproducible and robust high-throughput method for discovery of novel 
single nucleotide polymorphisms (SNPs) as well as small deletions or insertions with 
sensitivity comparable to that of direct DNA sequencing (30, 31) and superior to that of 
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alternative gel based analysis techniques (i.e. SSCP) (32). The principle behind the 
dHPLC method relies on detecting heteroduplex DNAs in PCR products amplified from 
genomic DNA in an individual that is heterozygous for a sequence variant. The 
sensitivity of heteroduplex detection relies on maintaining the dHPLC column at a 
specific temperature, which favors the increased thermodynamic instability of a PCR 
product with a single-base mismatch (i.e. a heteroduplex) (33, 34) over that of a PCR 
product containing perfectly matched base pairing (i.e. a homoduplex). DHPLC has been 
shown to clearly resolve mutations in various genes with detection rates ranging from 
92.5% to 100% (32, 35). 
Amplification of samples 
PCR products prepared from AGRE patient genomic DNA served as the DNA 
fragments analyzed for the presence of mutations. Primers were designed to amplify at 
least 15 bp flanking each intron/exon boundary for all coding regions of the candidate 
gene. These primer pairs were designed by examining annotated genomic sequence 
databases (http://genome.ucsc.edu and http://www.ncbi.nlm.nih.gov) and using Primer3, 
an online conventional primer design software package (http://www- 
genome.wi.mit.edu/cgi-bin/primer/primer3_www.cgi). Primers and sequences are listed 
in Appendix Table Al. Primers were produced by Invitrogen Corporation (Carlsbad, 
CA). 
Primers were optimized to one of six different annealing temperatures (55°C, 
56°C, 56.8°C, 58.1°C, 59.1°C, 60°C). Optimum annealing temperatures for each primer 
pair are listed in Appendix Table Al. 
V. 
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PCR conditions for the various primer pairs were as follows. Each reaction was 
performed in a total volume of 30 pi and contained 1 pi of DNA at 50 ng/pl, 15 pi of 
MasterAmp™ 2x PCR PreMix D Buffer (Epicentre Technologies, Madison, WI), 1 pi of 
10 nM forward primer, 1 pi of 10 nM reverse primer, and 0.125 pL of 5U/pl Taq DNA 
Polymerase (Roche Diagnostics Corporation, Indianapolis, IN). The PCR temperature 
program consisted of a 4 min hot start at 94°C followed by 30 cycles of 30 sec of 
denaturation at 94°C, 30 sec at the optimal annealing temperature (see Appendix Table 
Al), and 45 sec at 72°C for PCR product elongation. There was a final 10 min elongation 
step at 72°C, and then the reaction was stored at 4°C until ready to be analyzed by 
dHPLC. 
Variant screening using dHPLC 
Following PCR amplification, the samples were denatured at 95°C for 10 min and 
then cooled to 30°C over a period of 10 min to enhance the formation of DNA 
heteroduplexes. Samples were then run on a Transgenomic WAVE® dHPLC system with 
the DNASep® dHPLC column (Transgenomic, San Jose, CA). The WAVE system 
consists of a cooled 96-well autosampler, column oven, pumps, buffer degasser, variable 
wavelength UV detector, a 20-pl sample loop, and a PC-based data collection system. 
Chromatography on the WAVE system is performed with a dual buffer system, where the 
buffers used were as follows: Buffer A, 0.1 M triethylammonium acetate (TEAA, 
Transgenomic, San Jose, CA), pH 7.4, and Buffer B, 0.1 M TEAA and 25% acetonitrile 
(CAN, Transgenomic, San Jose, CA). Both the loading buffer and syringe wash solution 
consisted of 10% ACN for the DNASep column. In addition, the Transgenomic WAVE 
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system injects 200 pi of a 75% ACN column wash solution, of which 200 pi was injected 
after each run. TEAA, ACN, and water used for the preparation of buffers were of HPLC 
grade. 
Using this system, 7 pL of PCR product was loaded onto the preheated column 
and was eluted by an increasing acetonitrile gradient at a certain partially denaturing 
temperature which was specific to each PCR amplicon. All dHPLC conditions, including 
melting temperatures and buffer gradients specific to each PCR amplicon, were 
determined using the DHPLC Melt Program at http://insertion.stanford.edu/melt.html. 
Some amplicon fragments required dHPLC analysis at more than one temperature in 
order to detect possible mutations along the entire fragment (all DHPLC temperatures are 
listed in Appendix Table Al). Eluent flow rates for all analyses were 0.9 ml/min. Eluted 
DNA fragments were detected by UV absorption at a wavelength of 260 nm and were 
evaluated for abnormalities in elution profile as described below. 
Mutation Calling 
Sequence variations are identified based on a comparison between the 
chromatogram waveforms of wild type amplicons (i.e. no sequence variations) and 
chromatograms of amplicons carrying heterozygous mutations, recorded under identical 
dHPLC conditions. A characteristic example of mutation calling is illustrated in Figure 1. 
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B Wild Type SNP Carrier 
Figure 1. Duplex formation and dHPLC mutation screening. A. Mixtures of wild type (black) and 
mutant (grey) amplicons, which are either co-amplified during the PCR or generated by post-PCR mixing, 
are denatured by heating and reannealed by slow cooling, leading to the formation of four distinct species, 
two original homoduplexes and two heteroduplexes. Sequence variations resulting in heteroduplex 
formation include SNP as well as short insertions and deletions. B. Wild type and mutant homoduplexes 
melt at higher temperatures than mismatch containing wild type/mutant heteroduplexes. Differences in 
melting temperatures are the basis for the identification of mutations by dHPLC, which will display 
different waveforms based on different melting temperatures. 
The wild type chromatogram exhibits a typical single-peak pattern, 
because the amplified wild type sample contains a single homoduplex amplicon. 
With increasing analysis temperature, the PCR product progressively melts, 
resulting in a steady increase in its single-stranded character and causing a steady 
reduction in retention time on the DNASep column. This is the result of decreased 
affinity of single-stranded DNA to the column matrix as compared to double- 
stranded DNA. The single peak chromatogram of a wild type homoduplex serves 
as a reference for mutation calling. 
The presence of sequence variations (polymorphisms or mutations) in an 
amplicon leads to the formation of four distinct duplexes (Figure 1 A) during the 
, 
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denaturation and reannealing step preceding dHPLC screening. This presents on a 
chromatogram as the appearance of additional peaks (Figure IB). Because homoduplexes 
have higher melting temperatures than the corresponding mismatch-containing 
heteroduplexes, the retention time of peaks representing homoduplexes is always longer 
than the retention times of their heteroduplex counterparts under identical gradient 
conditions and at analysis temperatures at or near the melting temperature of the 
homoduplex. 
DNA sequencing of putative variants 
Those individual PCR samples that appeared to display a heteroduplex-type peak 
were sequenced to confirm the presence of a heterozygous DNA variant—either point 
mutation, SNP, insertion, or deletion. PCR products from the original reaction were 
purified and sequenced by Genaissance, Inc. (New Haven, CT). 
Sequencing data was viewed using the Sequencher software package (Gene 
Codes, Inc., Ann Arbor, MI) and each sequence was matched to the corresponding 
chromatogram waveform in order to confirm the presence of a DNA variant. For each 
sample in which a DNA variant was confirmed, a translated amino acid sequence was 
matched to a reference (wild type) amino acid sequence in order to determine whether the 
DNA variation would result in an amino acid change. 
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Statement regarding level of involvement 
I conducted all elements of this project, with the exception of patient recruitment, 
patient clinical evaluations, and karyotype analysis. As mentioned above, members of the 
clinical and research faculty and staff at the Yale Child Study Center and Department of 
Genetics recruited and evaluated the individual cases with known chromosomal 
abnormalities. Patient recruitment and clinical assessment of AGRE patients were 
completed by the AGRE and Cure Autism Now Foundation research teams (Los Angeles, 
CA). Karyotype analysis was performed by Nicole Davis, a cytogeneticist in the 
Department of Genetics and Child Study Center. 
RESULTS 
Case 1 - PDD and a balanced (3;10) translocation 
Clinical assessment 
CT is a boy aged 7 years 11 mo with borderline intellectual functioning, 
distinctive facial (Figure 2) and other physical features (Appendix Table A2), and 
behavioral problems who was seen in the Genetics Outpatient Clinic at Yale and 
evaluated under a research protocol approved by the Yale Human Investigation 
Committee with informed consent. The patient was the product of a non-consanguineous 
union, delivered at 40 weeks gestation from his 29 year-old primiparous mother by 
cesarean section performed because of failure to progress. There was no history of 
alcohol consumption or medication use during pregnancy and no known exposure to 
. 
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teratogens. He had a difficult facial presentation, with mild perinatal respiratory 
depression and an Apgar score of 3 at 1 min. Cord blood pH was 7.28. After brief 
positive pressure ventilation, his Apgar score was 9 at 5 min. Birth weight was 3,787 g 
and length was 19 inches. Cytogenetic analysis was performed shortly after birth, which 
revealed a balanced translocation [46, XY,t(3; 10)(p26;q26)]. Both parents had normal 
karyotypes. No other family members were reported to have mental retardation or 
dysmorphic features. 
The child's early motor development was unremarkable: he rolled over at 4 
months and was sitting with support at 6.5 months. At 7 months, he was able to stand 
with assistance, and he walked at 14 months. His development of language, in contrast, 
was markedly delayed, with the absence of distinct single words until 3.5 years. CT 
underwent a cognitive assessment at age 7 years 2 months and was found to have a full 
scale IQ of 73 on the Wechsler Intelligence Scale for Children, Third Edition (WISC-III) 
(Mean = 100; SD = 15), which places his cognitive skills within the borderline range of 
intellectual functioning. He obtained a verbal IQ of 81 and a performance (or nonverbal) 
IQ of 70. Significant weaknesses in his profile related to attention to visual detail (subtest 
score of 3; mean = 10, SD = 3), visual-spatial reconstruction skills (subtest score of 3), 
and understanding of social mores and expectations (subtest score of 3). These deficits 
contrasted with his significant strength in the area of fund of knowledge (subtest score of 
12). 
Vi 
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Figure 2. Case 1. Eight-year-old boy with developmental delay (PDD-NOS) and dysmorphic facial 
features. The child has had surgical correction of prominent ptosis and a notable low frontal hairline. 
(Photographs used with consent). 
Assessment of adaptive functioning at YCSC using the Vineland Adaptive 
Behavior Scales (22) showed impairments in all four domains of adaptive behavior 
covered by this test. His standard scores and percentile ranks (%) were as follows: 
communication 8 (14%), daily living skills 50 (<0.1%) socialization 66 (1%), and motor 
skills 76 (5%). His adaptive composite score, which summarizes performance across all 
of these domains, was 61 (0.5%). 
CT was also evaluated for autistic disorder using the Autism Diagnostic 
Interview-Revised (ADI-R) (20) and Autism Diagnostic Observation Schedule- Generic 
(ADOS-G) (21). ADI-R scores were as follows: communication 13 (threshold score for 
autism is 8), social interaction 25 (threshold score for autism is 10), stereotyped behavior 
3 (threshold score for autism is 3). ADOS-G scores were as follows: communication 
domain 2 (threshold score for autism is 3, for PDD-NOS is 2), social domain 4 (threshold 
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score for autism is 6, for PDD-NOS is 4), imagination/creativity 1 (no threshold scores 
proposed), stereotyped behaviors and restricted interests 1 (no threshold scores 
proposed). 
CT's past medical history was unremarkable. He was noted to be in excellent 
physical health and had required surgery only for correction of ptosis. He had been 
followed closely from a very young age by his pediatrician as a consequence of his 
dysmorphic features and known cytogenetic rearrangement and was not found to have 
any evidence of GI, cardiac, or renal abnonnalities on physical exam or by history. A 
referral to a pediatric neurologist for behavioral issues at age 6 years revealed a normal 
neurological exam, except for the identification of mild hypotonia. Neither neuroimaging 
nor electroencephalogram was deemed to be clinically indicated. 
Physical examination at age 7 years 11 months revealed a height of 115.6 cm (5th- 
10th percentile), a weight of 21.4 kg (5th percentile), and a head circumference of 52 cm 
(50 -75 percentile). The patient showed high myopia and astigmatism, a low frontal 
hairline with right upsweep, forehead hypertrichosis, and bushy eyebrows without frank 
synophrys. He was also noted to have surgically improved ptosis and slight epicanthal 
folds, a broad nasal bridge with mild hypertelorism (measured at +1.5 SD at age 21 mo), 
downslanting palpebral fissures, downtumed comers of the mouth, prominent but 
normal-sized ears with superior helices sagging downward, slight fifth-finger 
clinodactyly, branched transverse palmar crease of right hand, mild bilateral syndactyly 
of the second and third toes, hypertrichosis of his thighs and legs, and mild hypotonia. 
Deep tendon reflexes were normal. 
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Cytogenetic analysis 
Molecular studies were undertaken to fine map the (3; 10) translocation using 
FISH. Several probes mapping centromeric and telomeric to the translocation breakpoints 
on both chromosomes were identified (Table 1). Subsequent to the identification of 
BACs mapping on both sides of the translocation breakpoint on each chromosome, BACs 
within the translocation intervals were used, eventually identifying probes spanning both 
the chromosome 3 and 10 breakpoints (Figures 3 and 4). Two BACs spanning the 
chromosome 3 breakpoint, RPCI-11 299N33 and RPCI-11 121K9, were found to map in 
their entirety to the first intron of the gene Contactin 4 (CNTN4 [MIM 607280]) (Figure 
4A), establishing that the translocation breakpoint disrupted the gene within the 5’ 
untranslated region (UTR) of the mature CNTN4 mRNA. 
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Table 1. Case 1: BAC probes investigated using fluorescence in situ hybridizationA 
BAC ID 
Base position 
(July 2003 Freeze) 
Chromosomal 
band 
Location relative 
to breakpoint 
RP11-1082A18 chr3:10,298,689-10,516,466 3p25.3 centromeric 
RP11-572M14 chr3:10,011,785-10,180,797 3p25.3 centromeric 
RP11-1020A11 chr3:9,778,862-9,995,772 3p25.3 centromeric 
RP11-19E8 chr3:8,917,083-9,067,340 3p25.3 centromeric 
RP11-128A5 chr3:8,686,926-8,857,271 3p25.3 centromeric 
RP11-34L16 chr3:8,442,935-8,594,857 3p25.3 centromeric 
RP11-470E10 chr3:7,841,368-8,025,425 3p26.1 centromeric 
RP11-507D6 chr3:6,997,984-7,199,514 3p26.1 centromeric 
RP11-318114 chr3:6,283,022-6,437,405 3p26.1 centromeric 
RP11-161L3 chr3:5,744,835-5,909,633 3p26.1 centromeric 
RP11-129J10 chr3:5,027,803-5,180,950 3p26.1 centromeric 
RP11-453 A3 chr3:4,15 8,926-4,329,972 3p26.1 centromeric 
RP11-245A6 chr3:3,545,257-3,707,298 3p26.2 centromeric 
RP11-198P17 chr3:2,928,181-3,117,274 3p26.2 centromeric 
RP11-94M9 chr3:2,804,247-2,975,122 3p26.2 centromeric 
RP11-785A7 chr3:2,690,183-2,862,993 3p26.2-3p26.3 centromeric 
RP11-8203 chr3:2,566,282-2,742,197 3p26.3 centromeric 
RP11-6301 chr3:2,443,361-2,617,387 3p26.3 centromeric 
RP11-211K13 chr3:2,307,996-2,470,413 3p26.3 centromeric 
RP11-762012 chr3:2,287,581 -2,441,071 3p26.3 centromeric 
RP11-299N3 chr3:2,181,279-2,367,269 3p26.3 spanning 
RP11-129K1 chr3:2,132,133-2,290,752 3p26.3 spanning 
RP11-176P14 chr3:2,021,987-2,193,951 3p26.3 telomeric 
RP11-416N8 chr3:l,244,095-1,420,317 3p26.3 telomeric 
RP11-392M7 chr3:1,064,436-1,252,749 3p26.3 telomeric 
RP11-114K9 chr3:333,643-518,322 3p26.3 telomeric 
RP11-306H5 chr3:159,323-343,406 3p26.3 telomeric 
RP11-338L11 chrlO: 116,448,883-116,645,816 10q25.3 centromeric 
RP11-169K19 chrlO: 117,157,040-117,301,164 10q25.3 centromeric 
RP11-96N16 chrlO: 117,471,461-117,637,580 10q25.3 centromeric 
RP 11-295023 chrlO: 117,733,868-117,949,898 10q25.3 centromeric 
RP11-498B4 chrl0:l 18,011,104-118,209,364 10q25.3 centromeric 
RP11-5G18 chrlO: 118,364,598-118,528,414 10q25.3-10q26.11 centromeric 
RP11-328K15 chrl0:l 19,130,080-119,172,006 10q26.11 centromeric 
RP11-355F22 chrl0:l 19,170,007-119,301,205 10q26.11 spanning 
RP11-13617 chrl0:l 19,181,243-119,340,828 10q26.11 spanning 
RP11-280F22 chrlO: 119,299,202-119,400,731 10q26.11 telomeric 
RP11-3H12 chrlO: 119,316,263-119,394,906 10q26.11 telomeric 
RP11-354M20 chrl0:l 19,398,732-119,592,400 10q26.11 telomeric 
A BAC probes used for FISH analysis: The RPCI-11 identifiers, chromosome number and band, location in 
base pairs (July 2003 freeze), and position determined relative to the breakpomt(s) are shown for all BACs 
hybridized. BAC probes noted as centromeric and telomeric yielded two hybridization signals on 
metaphase spreads. Spanning probes resulted in three hybridization signals 
v. 
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Figure 3. Cytogenetic and molecular cytogenetic studies of a de novo (3;10) translocation 
(Case 1). A. G-banded karyotype of the patient's lymphocytes showing a t(3p26;10q26) translocation. 
Arrows highlight the breakpoints on the respective chromosomes, and dotted lines show the corresponding 
position on the ideograms. 10/10 metaphase spreads examined showed the identical translocation. B. BAC 
probe 299N3 (red) spanning the chromosome 3p breakpoint. Hybridization signals are seen on both normal 
and derivative chromosomes 3. A third red hybridization signal is also seen on the derivative chromosome 
10, as a result of the breakpoint transecting the region corresponding to the experimental probe. A control 
probe (green) maps to the q arm of chromosome 3. C. Probe 355F22 (red) spanning the chromosome lOq 
breakpoint. Hybridization signals are present on the normal and derivative chromosomes 10. A third red 
signal is seen on the telomeric region of chromosome 3. Control probes (green) map to the short arm of 
chromosome 3. D. Subtelomeric FISH results are shown. Chromosome 10 probes are in the left box—the 
normal (nl) chromosome 10 with both green and red probes, the derivative (der) 10 with only a green probe, 
and the derivative chromosome 3 with only the red probe are shown. The box on the right shows 
chromosome 3 probes, with the normal chromosome showing both red and green probes, the derivative 3 
showing only the red probe, and the derivative 10 showing only the green probe. 
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Figure 4. Diagram of chromosomes 3 and 10 breakpoints (Case 1). A. Telomeric region of chromosome 
3 from3p26.1 to 3p26.3, represented by the grey and white bar at the top of the diagram. Relevant STS 
markers are in black text, and known genes from the RefSeq database are in blue text. The region 
corresponding to CNTN4 is pictured as a blue shaded rectangle. Distances noted were derived from the July 
2003 freeze of the Human Genome Project and include: (1) the 1.69 Mb-interval from the 3’-most exon of 
CHL1 to exon 1 ofCNTN4; (2) the 0.69-Mb interval from the 3’-mostexon of CNTN6 to exon 1 of 
CNTN4; (3) the 4.5-Mb interval defined by Cargile et al. (2002) as the smallest interstitial deletion 
identified in a 3p deletion syndrome case; and (4) the 6.7-cM interval identified by Higgins et al. (2002) in a 
large pedigree affected with nonspecific mental retardation (Zmax =9.18 at marker D3S3050). The bar below 
the genomic interval shows detail of the region, including exons of CNTN4 (in red). Selected BACs are 
noted as dark horizontal bars beneath. The breakpoint interval is shown as a red rectangle. The position of 
each BAC probe relative to the breakpoint on chromosome 3 is indicated below the RPCI-11 library 
identifier. The distance for the entire genomic interval corresponding to CNTN4 is indicated below the thin 
black line. B. Chromosome 10 in the region from 10q25.3-10q26.12, represented by the grey and white bar 
at the top of the diagram. Known genes from the RefSeq database are noted in blue. The 0.46-Mb distance 
between the 3’-mostexon of EMX2 and the 5’-most exon ofRabl 1-FIP2 was determined by the July 2003 
freeze of the Human Genome Project. The lower bar shows details of the interval, with the relative position 
of known genes in the region in blue text. The breakpoint region is highlighted with a red rectangle. No 
known genes or spliced ESTs were identified on the BAC spanning the chromosome 10 breakpoint. BACs 
from the region are identified as dark horizontal lines below the genomic region, with their position relative 
to the breakpoint on chromosome 10 noted below their RPCI identifiers. 
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BACs RPCI-11 355F22 (Figures 3 and 4) and RPCI-11 13617 were found to span 
the chromosome 10 translocation breakpoint. This chromosome segment lies within a 
gene-poor region in the band 10q26.11 (Figure 4B). No known or predicted transcripts or 
spliced ESTs were identified on these clones with the use of the UCSC genome browser. 
Five distinct ESTs without canonical splice sites were mapped to the BAC. Efforts to 
extend these fragments in silico with the use of the BLAST server at the National Center 
for Biotechnology Information (http://www.ncbi.nlm.nih.gov/blast/) were unsuccessful, 
and four of these five fragments showed no significant homology to other human ESTs or 
known genes. 
Additional FISH studies were undertaken to evaluate the regions telomeric and 
centromeric to the 3p translocation (Table 1). These resulted in no evidence of a deletion. 
Subtelomeric FISH with the use of commercially available probes was also performed to 
confirm the integrity of the terminal regions of the normal and derivative chromosomes 3 
and 10 (Figure 3). FISH mapping of BACs corresponding to the two closest transcripts 
on the telomeric aspect of the breakpoint, CHL1 (Close Homologue of LI, also known as 
CALL [MIM 607416]) and CNTN6 (MIM 607220), each showed the expected pattern of 
two hybridization signals, and direct sequencing of CNTN4 in the patient demonstrated 
no mutations in the coding regions of the remaining, intact transcript (data not shown). 
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Cases 2-4 - autism and a balanced (4;10) translocation 
Clinical Assessment 
SG (female, age 7 y 3 mo), WG (male, age 7 y 3 mo), and AG (female, age 6 y 1 mo) 
were evaluated at the Yale Child Study Center (YCSC) under a research protocol 
approved by the Yale Human Investigations Committee with informed consent. These 
were the only offspring of a non-consanguineous union, delivered at 34, 34, and 40 
weeks, respectively. There was no history of alcohol consumption or medication use 
during pregnancy, and no known exposure to teratogens. No other family members were 
reported to have mental retardation or autism, although a maternal cousin was reported to 
have attentional and social difficulties. 
Assessment of adaptive functioning at YCSC using the Vineland Adaptive Behavior 
Scales (22) showed marked impairments in communication, daily living skills 
socialization, and motor skills, with percentile rank scores <0.1 for all three children 
across all domains. Adaptive composite scores (all with percentile rank <0.1) were as 
follows: SG, 29; WG, 28; AG, 34. 
All children were also evaluated for autistic disorder using the Autism Diagnostic 
Interview-Revised (ADI-R) (20) and Autism Diagnostic Observation Schedule (ADOS) 
(26). All three children met criteria for autistic disorder by scores on both scales. ADI 
scores for SG, WG, and AG, respectively, were as follows: communication and language 
14, 19, 9 (threshold score for autism is 7), social interaction 24, 23, 16 (threshold score 
for autism is 10), stereotyped behavior 3, 4, 4 (threshold score for autism is 3). Two 
different versions of the ADOS were used (21, 26). ADOS scores for SG and WG, 
V. 
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respectively, were as follows: communication domain 10, 8 (threshold score for autism is 
4), social domain 14, 14 (threshold score for autism is 7), total 24, 22 (threshold score for 
autism is 12). ADOS scores for AG were: communication domain 10 (threshold score for 
autism is 5), social domain 14 (threshold score for autism is 6), total 24 (threshold score 
for autism is 12). 
Cytogenetic analysis 
Cytogenetic analysis revealed a balanced translocation [46, XX, t(4;l 1 )(q25;p 15)] in 
both affected female siblings and their unaffected mother (Figure 5). An apparently 
identical translocation [46, XY, t(4;l 1 )(q25;p 15)] was found in the affected male sibling. 
The unaffected father had a normal karyotype. 
Figure 5. Ideogram of balanced translocation in Cases 2-4: Diagram of chromosomes 4 and 11, showing 
the balanced translocation t(4;l 1 )(q25;p 15). Nml 4 and nml 11 = normal chromosomes 4 and 11. Der 4 and 
der 11 = derivative chromosomes 4 and 11 with exchange of genetic material. Chromosomes and pieces 
outlined in red = chromosome 4; chromosomes and pieces outlined in yellow = chromosome 11. Karyotype 
images of corresponding G-banded chromosomes are shown adjacent to ideograms. 
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In all four chromosomal rearrangements, the location of the breakpoint on 
chromosome 4q25 was mapped to within a 148 kb region (Figure 6, Table 2 in 
Appendix). One known gene (RPL34) was localized to this region based on the NCBI 
Ref Seq database at http://www.ncbi.nlm.nih.gov/RefSeq/. This gene is known to code 
for a ribosomal protein with moderate expression levels in brain 
(http://www.ncbi.nlm.nih.gov/UniGene). 
The location of the breakpoint on chromosome 1 lp 15.4 was mapped to within a 67 
kb region (Figure 6, Table 2). Two predicted genes (FLJ32752 and KIAA0409) map 
within this interval based on the NCBI Ref Seq database at 
http://www.ncbi.nlm.nih.gov/RefSeq/. FLJ32752 encodes a hypothetical protein involved 
with microtubule motor activity in embryo with no apparent brain expression. KIAA0409 
encodes a brain expressed hypothetical protein (Cerebral protein-1) that appears to 
belong to a family of uncharacterized eukaryotic proteins which are related to 
methyltransferases (http://www.sanger.ac.uk/Software/Pfam/iPfam/). 
Evaluation of copy number changes using the GeneChip Mapping 1OOK Set array 
revealed no areas of deletion or duplication on 4q25 or 1 lp 15.4 (data not shown). 
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Figure 6. Fine-mapping breakpoints of a (4; 11) translocation (Cases 2-4). A. Metaphase cell from 
mother under fluorescent microscopy with locations of human BAC probes indicated. Aqua (DEAC) probe 
hybridized to the normal chromosome 4 and the derivative chromosome 11, indicating that this BAC probe 
is telomeric to the breakpoint on chromosome 4. Red (Cy3) probe hybridized to nl chromosome 4, der 
chromosome 11, and der chromosome 4, indicating that this BAC probe spans the breakpoint on 
chromosome 4. B. Ideogram of chromosome 4, illustrating the positions of spanning Cy3 (RP11-462C24) 
and RP11-501L16 probes on a normal chromosome 4. One known gene (RPL34) exists in the 148 kb 
breakpoint interval (yellow shaded region). C=centromeric, s=spanning, t=telomeric BACs. C.. Metaphase 
cell from mother under fluorescent microscopy with locations of human BAC probes indicated. Aqua 
(DEAC) and red (Cy3) probes both hybridized to the normal chromosome 11, the derivative chromosome 
11, and the derivative chromosome 4, indicating that this BAC probe spans the breakpoint on chromosome 
11. Green (FITC) probe was used as a control, hybridizing to 11 p 15 centromeric to the breakpoint. D. 
Ideogram of chromosome 11, illustrating the positions of spanning (s) DEAC (RP11-106K18), Cy3 (RP11- 
8906), and other BAC probes on a normal chromosome 11. Two predicted genes (FLJ32752 and 
KIAA0409) exist in the 67 kb breakpoint (yellow shaded) region. 
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Table 2. Cases 2-4: BAC probes investigated using fluorescence in situ hybridization15 
BAC ID 
Base position 
(July 2003 Freeze) 
Chromosomal 
band 
Location relative 
to breakpoint 
RP11-297P16 chr4:104,864,485-105,048,993 4q24 centromeric 
RP11-41F9 chr4:107,451,468-107,574,511 4q24 centromeric 
RP11-713M16 chr4:108,552,432-108,690,056 4q25 centromeric 
RP11-286E11 chr4:109,166,532-109,329,848 4q25 centromeric 
RP11-343N16 chr4:109,378,308-109,535,867 4q25 centromeric 
RP11-558N14 clir4:109,523,271-109,659,770 4q25 centromeric 
RP11-349123 chr4:109,824,239-109,858,719 4q25 centromeric 
RP11-111A14 chr4:109,713,916-109,881,949 4q25 centromeric 
RP11-501L16 chr4:109,856,719-110,060,415 4q25 spanning 
RP11-462C24 chr4:109,856,720-110,008,699 4q25 spanning 
RP11-348N12 chr4:l 10,006,700-110,117,493 4q25 telomeric 
RP11-75N20 chr4:l 10,116,399-110,266,975 4q25 telomeric 
RP11-602N24 chr4:l 11,111,779-111,230,409 4q25 telomeric 
RP11-650J17 chr4:l 14,303,368-114,520,237 4q25 telomeric 
RP11-746C23 chrl 1:12,530,466-12,718,542 1 lp 15.3 centromeric 
RP11-483L5 chrl 1:11,387,947-11,600,728 1 lpl 5.4 centromeric 
RP11-58H20 chrl 1:10,534,231-10,699,928 1 lpl 5.4 centromeric 
RP11-467K18 cirri 1:8,971,792-9,166,478 1 lpl5.4 centromeric 
RP11-321F11 chrl 1:8,371,551-8,539,322 11 p 15.4 centromeric 
RP11-494M8 chrl 1:7,764,989-7,959,247 11 p 15.4 centromeric 
RP11-324J3 chrl 1:7,101,122-7,273,393 11 p 15.4 centromeric 
RP11-413N10 cirri 1:6,909,050-7,077,179 1 lpl 5.4 centromeric 
RP11-732A19 chrl 1:6,588,043-6,799,812 1 lpl5.4 centromeric 
RP11-291013 chrl 1:6,551,174-6,706,742 1 lpl 5.4 spanning 
RP11-106K18 chrl 1:6,520,599-6,704,383 11 p 15.4 spanning 
RP 11-8906 chrl 1:6,480,882-6,650,346 1 lpl 5.4 spanning 
RP11-270J8 chrl 1:6,452,777-6,633,889 11 p 15.4 spanning 
RP11-114B9 chrl 1:6,438,904-6,611,366 11 p 15.4 spanning 
RP11-1061L23 cirri 1:6,392,587-6,577,701 1 lpl 5.4 spanning 
RP11-211E17 chrl 1:6,441,702-6,633,943 1 Ip 15.4 spanning 
RP11-478A13 chrl 1:6,254,509-6,463,471 1 lp 15.4 telomeric 
RP11-304C12 chrl 1:6,247,139-6,438,805 1 lpl 5.4 telomeric 
RP11-290F24 chrl 1:6,069,305-6,255,908 11 p 15.4 telomeric 
RP11-451K18 chrl 1:5,958,461-6,124,142 1 lpl5.4 telomeric 
RP11-437G21 chrl 1:4,204,393-4,407,348 11 p 15.4 telomeric 
RP11-23F23 chrl 1:4,020,255-4,202,776 1 lpl 5.4 telomeric 
RP11-438N5 chrl 1:3,861,913-4,013,518 1 lpl 5.4 telomeric 
RP11-348A20 chrl 1:3,678,516-3,843,974 1 lp 15.4 telomeric 
RP11-11A9 chrl 1:3,200,821-3,320,380 1 lpl 5.4 telomeric 
B BAC probes used for FISH analysis: The RPCI-11 identifiers, chromosome number and 
band, location in base pairs (July 2003 freeze), and position determined relative to the 
breakpoint(s) are shown for all BACs hybridized. BAC probes noted as centromeric and 
telomeric yielded two hybridization signals on metaphase spreads. Spanning probes 
resulted in three hybridization signals. 
. 
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Mutation screening of CNTN4 
Based on the finding of a direct disruption of the CNTN4 gene in a patient (Case 1 
above) with an autistic spectrum disorder (PDD-NOS), genomic DNA from 97 AGRE 
sample patients was screened via dHPLC for mutations in the coding exons of CNTN4. 
These patients all had no known cytogenetic abnormalities and had at least one 
dysmorphic facial feature in common with patient CT (see Appendix Table A2). The 
cohort of 97 patients selected included those with a diagnosis of autism (N=78), “broad 
spectrum” (N=13) and “not quite autism” (NQA, N=6). 
Primers were designed to amplify exons and flanking regions of CNTN4 (see 
“Amplification of samples” in Materials and Methods section). Forward and reverse 
primer sequences for each exon, the resulting amplicon size, and PCR annealing 
temperatures are listed in Appendix Table Al. 
Following PCR amplification of each exon, each sample was screened for 
heterozygous variants using dHPLC methods described above. DHPLC running 
temperature(s) for each amplicon are listed in Appendix Table Al. Results to-date for this 
mutation screening of 97 AGRE patients are summarized in Table 3. Based on a 
comparison of dHPLC chromatogram waveforms for each amplicon, samples with 
unique-looking variants were identified as candidates for sequencing in order to confirm 
a suspected heterozygous locus. Based on all samples to-date that have successfully 
completed dHPLC screening and sequencing of at least one sample representing their 
unique chromatogram waveform appearance, several heterozygous loci have been 
confirmed (see Table 3). 
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Table 3. Mutation screening of CNTN4 in AGRE cohort (N=97), by amplicon 
Amplicon 
Coding/ 
non-coding 
# samples 
completed 
dHPLC 
# samples 
candidates for 
sequencing 
# samples 
completed 
full screen 
# heterozygous 
loci detected 
Exon 1 Non-coding 93 13 0 
Exon 2 Non-coding 84 9 82 0 
Exon 3 Coding 96 6 96 0 
Exon 4 Coding 46 7 46 0 
Exon 5 Coding 81 9 31 0 
Exon 6 Coding 97 7 97 lc 
Exon 7 Coding 79 16 60 0 
Exon 8 Coding 91 7 89 1D 
Exon 9 Coding 90 15 90 0 
Exon 10 Coding 75 7 75 0 
Exon 11 Coding 90 10 90 0 
Exon 12 Coding 95 7 0 - 
Exon 13 Coding 96 7 0 - 
Exon 14 Coding 97 8 0 - 
Exon 15 Coding 93 4 93 0 
Exon 16 Coding 80 5 0 - 
Exon 17 Coding 97 11 0 - 
Exon 18 Coding 97 7 97 0 
Exon 19 Coding 97 30 0 - 
Exon 20 Coding 65 16 65 0 
Exon 21 Coding 97 15 95 37e 
Exon 22 Coding 85 10 85 0 
Exon 23 Coding 97 11 88 0 
Exon 24a Coding 79 19 79 0 
Exon 24b Non-coding 97 13 0 - 
Exon 24c Non-coding 97 12 0 - 
Exon 24d Non-coding 93 7 0 - 
Exon 24e Non-coding 97 7 0 - 
Exon 24f Non-coding 97 16 0 - 
Exon 24g Non-coding 97 19 0 - 
c 
Sequencing in both directions confirmed presence of a heterozygous, missense, A->G 
mutation in base 101 of exon 6 (A723947G). See Figure 7 for details. 
D Sequencing in one direction indicated a unique variant within intronic sequence 
following 3’ end of exon 8 (IVS8+13 T>G). See Figure 9 A. 
E Sequencing several candidate samples revealed a common intronic SNP before 5’ exon 
21 (IVS21-8 C>T). All samples with matching dHPLC waveforms were inferred to carry 
the same variation. See Figure 9B. 
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One autistic patient was found to have a missense point mutation A723947G 
(A^G heterozygous change at nucleotide 723947 of CNTN4, or nucleotide 101 of exon 
6). The dHPLC chromatogram and heterozygous sequence chromatogram are shown in 
Figure 7. This base change results in an amino acid change (Thr->Ala) at position 128 of 
the CNTN4 protein (Figure 7C). This amino acid is located within the second of six 
immunoglobulin-like C2-type domains of the protein. A pedigree for the Caucasian 
family of this proband is shown in Figure 8A. Sequencing exon 6 of CNTN4 in each 
family member revealed an identical heterozygous A723947G mutation in an autistic 
sister, unaffected sister, and unaffected mother of the autistic proband (Figure 8B). This 
exon was also sequenced in 234 Caucasian controls and no mutations were found. 
B C 
WT 
MUT 
AGA ACA AGA 
R T R 
AGA GCA AGA 
R A R 
Figure 7. Detection of a missense mutation in exon 6 of CNTN4 in one autistic patient. A. dHPLC 
chromatograms show wild type (non-mutated) waveform along with the mutation or variant waveform 
produced by the DNA of this autistic patient when screening for mutations in exon 6 of CNTN4. Based on 
the waveform variation, this sample was flagged as a candidate for sequencing. B. Sequencing 
chromatogram for this autistic patient, showing the heterozygous nucleotide change in exon 6 (A723947G). 
C. This nucleotide change produces a missense mutation, causing an amino acid change in the CNTN4 
protein (Thrl28Ala). This amino acid is known to be in the second of six immunoglobulin-like C2-type 
domains which make up the protein. 
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A 
2, 5, 7, 8 (WT) 
1,3, 4, 6 (Mut) 
Figure 8. Screening AGRE family for CNTN4 exon 6 missense mutation. A. Pedigree of AGRE family 
AU0700 containing index autistic proband (sibling 3 with arrow) who was discovered to have a missense 
mutation A723947G in exon 6 of CNTN4 (see Figure 7). Pedigree shows affected status of all members. 
Aut=autism, NQA=not quite autism, UA=unaffected. Asterisks indicate those individuals who carry a 
heterozygous A723947G missense mutation: two autistic sisters (3, 4), one unaffected sister (6), and 
unaffected mother (1). B. Sequence chromatograms for family members without the mutation (2, 5, 7, 8) 
and those with the A->G heterozygous mutation (1, 3, 4, 6). 
In addition, a different autistic patient was found to have a unique T~>G variant 
which is located in an intron , 13 nucleotides away from the 3’ end of exon 8 (IVS8+13 
T>G, Figure 9A). Because this variant is intronic, it is not transcribed into mRNA, and 
therefore is not involved in coding for an amino acid in the translated protein. A search of 
online SNP databases (http://www.ncbi.nlm.nih.gov/SNP) does not reveal any recorded 
information about this particular single nucleotide change, so population frequency is not 
known. 
Finally, 37 autistic, “broad spectrum” and “not quite autism” patients were found 
to have a C-^T variant in an intron, 8 nucleotides away from the 5’ end of exon 21 
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(IVS21-8 OT, Figure 9B). This non-coding variant is recorded in online SNP databases 
(refSNP ID 6800354) as having an average allele frequency of 0.17. 
B 
T TTCTTHGGT 
(’^ T SNP in V end of 
intron sequence exon 21 
Figure 9. Heterozygous intronic variants in CNTN4 detected by dHPLC and confirmed with 
sequencing. A. Sequencing chromatogram of one autistic patient with heterozygous intronic variant, 
located 13 nucleotides away from the 3’ end of CNTN4 exon 8 (IVS8+13 T>G). This variant has not been 
previously reported in online SNP databases. B. Sequencing chromatogram from one of 37 autistic, broad 
spectrum, and NQA patients with identical dHPLC chromatograms (not shown). The sequence reveals a 
heterozygous intronic SNP, located 8 nucleotides away from the 5’ end of CNTN4 exon 21 (IVS21-8 C>T) 
This SNP has been previously reported in the general population (refSNP ID 6800354), with an estimated 
(T) allele frequency of 0.17. 
DISCUSSION 
Over the last decade, many studies have aimed to identify genetic susceptibility loci 
for developmental neuropsychiatric disorders. The importance of molecular genetic 
findings lie in their ability to increase our understanding of the underlying pathology, 
improve diagnosis and genetic counseling, and eventually lead to new strategies of 
prevention and treatment (9). While linkage studies have been very successful for 
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mapping disease loci corresponding to rare disorders with Mendelian inheritance 
patterns, the field of psychiatric genetics has been less successful in attempts to find 
relevant genes for relatively common, complex disorders using this method. For autism 
and ASDs, the several independent linkage studies published to date have produced 
nominal to suggestive linkage evidence on varied chromosomes, with few regions of 
overlap between studies. Genetic and phenotypic heterogeneity in ASDs, combined with 
potentially inadequate sample sizes, has limited the power of non-parametric linkage 
methods to detect genes of small effect in these disorders. 
An alternative approach to identifying genetic susceptibility loci for autism involves 
the characterization of rare affected individuals who present with chromosomal 
abnormalities. Candidate genes at or near chromosomal breakpoints may be further 
investigated by mutation analysis and association studies. This approach has proven 
successful in identifying mutations in NLGN4 as rare genetic variants conferring 
susceptibility to ASDs (14, 15). Important genetic variants such as those in NLGN4 
would not be detectable using other more traditional methods of disease gene 
identification (e.g.. linkage), owing to the insufficient power of these methods to detect 
variants that occur relatively infrequently. Discovering such variants, even if rare, is 
enormously important in progressing toward a thorough understanding of genetic risk for 
complex, multigenic disorders such as many of those encountered in psychiatry. 
Furthermore, defining the role of genetic factors will allow us to better evaluate the role 
of non-genetic (i.e. environmental) factors that certainly contribute to disease 
susceptibility. 
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Case 1 
Based on standardized testing at the YCSC, CT met cutoff scores for a DSM-IV 
diagnosis of Pervasive Developmental Disorder-Not Otherwise Specified (PDD-NOS), 
which is categorized as one of several autism spectrum disorders (ASDs) (25). In 
addition, CT’s clinical presentation, including developmental delay, growth retardation, 
and ptosis, in combination with the known cytogenetic abnormality, suggested a 
diagnosis of 3p deletion syndrome. Appendix Table A2 lists the features of this 
syndrome, indicating those present in CT. Those physical signs not present in this case 
(e.g. trigonocephaly, microcephaly, micrognathia) are not ubiquitous findings in other 
reported cases in the literature. The patient's particular cognitive findings are mirrored in 
at least one other case in which the patient was found to have a full scale IQ in the 
borderline mental retardation (MR) range with what appeared to be significant 
weaknesses in adaptive functioning (36). In addition, a marked delay in early language 
acquisition, as seen in the present case, frequently has been noted anecdotally. However, 
a more detailed comparison of CT's cognitive findings with other reported cases is not 
possible, as a result of the informal descriptions of developmental delay that characterize 
the 3p deletion syndrome literature. From reports in the literature, it is apparent that 
phenotypic variability in all aspects of the syndrome appears to be the rule rather than the 
exception (37-43). 
CT meets criteria for borderline MR, PDD-NOS, and 3p deletion syndrome. In 
this case, the finding of disruption of CNTN4 is of particular interest since it maps both 
within the minimal candidate region for 3p deletion syndrome defined by Cargile et 
. 
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al.(44) and within a 6.7-cM region found linked to nonspecific mental retardation in large 
kindred (Zmax = 9.18 at marker D3S3050) (45) (Figure 4A). This gene encodes a 
neuronal adhesion molecule that is a member of the immunoglobulin (Ig) superfamily of 
genes. Similar to other members of the contactin family, which includes F3/F11/contactin 
(MIM 600316), TAG-1 (CNTN2 [MIM 190197]), BIG-1 (CNTN3 [MIM 601325]), NB-2 
(CNTN5 [MIM 607219]), and NB-3 (CNTN6), full-length CNTN4 consists of six 
immunoglobulin (Ig) domains and four fibronectin III (FNIII) domains and is anchored to 
the cell membrane via a glycosylphosphatidyl-inositol (GPI) domain. This family of 
proteins has been shown to be involved in axon growth, guidance, and fasciculation (46- 
49) and have been proposed to have a role in synaptic plasticity (50). While a specific 
role for CNTN4 in neuronal development has not yet been clarified, knockouts of 
homologous neuronal adhesion molecules in mouse have resulted in viable mutants 
demonstrating morphological, neurological, and behavioral abnormalities (51-54). 
While three isoforms of CNTN4 are described in the NCBI RefSeq database 
(http://www.ncbi.nlm.nih.gov/RefSeq), the identified breakpoint in this case disrupts only 
the longest variant, which is highly expressed in human brain, particularly in cerebellum, 
thalamus, amygdala, and cerebral cortex. The intermediate-sized isoform has not been 
found to be expressed in the CNS, while the third, shortest variant, lacking all six Ig and 
three FNIII domains, shows low levels of brain expression on northern blot and RT-PCR 
analysis (49, 55). Given the unavailability of brain tissue, it was not possible to directly 
test whether the current translocation altered expression of this short brain-expressed 
variant, despite the transcript remaining structurally intact. However, the likelihood of 
this short variant being able to compensate for the disruption of the full-length isoform is 
. 
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unlikely for several reasons. First, this short variant lacks all Ig and several FNIII 
domains which, in the full-length iso form, participate in a complex pattern of homophilic 
and hetetrophilic interactions that are required for axon growth and pathfinding. Second, 
the short isoform displays low levels of brain expression that are confined to the cerebral 
cortex, with little expression overlap with that of the longest isoform. Finally, the 
phenotypic features seen with CT overlap with those seen in cases where the terminal 
region of chromosome 3 is deleted. For these reasons, it is most likely that interruption of 
the longest CNTN4 isoform alone is sufficient to result in functional haploinsufficiency at 
this locus. 
The region telomeric to CNTN4 contains two genes (CNTN6 and CHL1) that also 
encode neuronal cell adhesion molecules with Ig and FNIII domains (Figure 4A). Given 
their similarity and proximity to the breakpoint locus in this case, and noting a report of a 
patient with nonspecific MR and a balanced translocation disrupting CHL1 (56) as well 
as reports of CHL1 knockout mice displaying abnormalities of behavior and axonal 
organization, it seems possible that the chromosomal translocation disrupting CNTN4 in 
this case may functionally disrupt these neighboring genes and lead to CT’s phenotype. 
While such position effects are certainly possible (57), one should note that in the single 
reported case of MR associated with CHL1 disruption, the patient did not display any 
dysmorphic features associated with the 3p deletion syndrome (56). In addition, the 3p- 
minimal candidate region suggested by Cargile et al.(44) includes CNTN4, but neither 
CNTN6 nor CHL1 (Figure 4A). 
Finally, it is noteworthy that a previous analysis of an extended pedigree 
identified evidence for a recessive locus conferring nonspecific MR within a 6.7 cM 
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linkage interval, and this region contained CNTN4 (Figure 4 A) (45). The finding of direct 
structural disruption of CNTN4 in CT together with these additional lines of evidence all 
converge upon the most likely scenario and main conclusion from this case: disruption of 
a single copy of CNTN4 is sufficient to cause key aspects of the 3p deletion syndrome 
phenotype, including developmental delay. 
Mutation screening of CNTN4 
Given the finding and evidence described above, the disruption of CNTN4 in a 
patient with borderline MR, an autism spectrum phenotype (PDD), and 3p deletion 
syndrome provides a rationale for mutation screening of CNTN4 in selected patients with 
developmental delay and dysmorphic features who have normal karyotypes. DNA from a 
cohort of 97 patients with autism and ASDs from the AGRE repository was screened for 
mutations in the exons of CNTN4. Each of these patients had one or more dysmorphic 
physical features in common with the patient described in Case 1 (see Appendix Table 
A2 and Figure 2) and no known cytogenetic abnormalities. One Caucasian autistic patient 
from this cohort was found to have a missense (amino acid changing) heterozygous point 
mutation in exon 6 of CNTN4 (Table 3 and Figure 7), which was not found in any of 234 
Caucasian normal controls who were sequenced for exon 6. In this case, it is conceivable 
that the mutation T723947G, resulting in a Thrl28Ala amino acid substitution, may alter 
the function of the CNTN4 protein, as it alters a highly conserved amino acid in the 
second of 6 functional Ig-like C2-type domains. 
* 
'• 
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The proband in whom this mutation was detected was one of six siblings in a 
multiplex ASD family (Figure 8A). Sequencing each member of the immediate family 
for the T723947G mutation in CNTN4 revealed three additional family members with the 
mutation (one autistic sister, one unaffected sister, and the unaffected mother). It appears 
that this mutation does not completely co-segregate with an autism or ASD diagnosis in 
this family. While such co-segregation would lend convincing evidence to the argument 
that this particular mutation is associated with autism in this family, lack of co¬ 
segregation does not necessarily exclude this possibility. One probable explanation is that 
this missense mutation may increase susceptibility to autism or ASDs, but is not the sole 
cause. The genetic change resulting from this mutation may be compounded by other 
genetic and non-genetic factors in those affected, such as a secondary mutation, or 
environmental factors, such as exposure to pathogens or teratogens, that increase the 
likelihood of developing autism in this family. Second, the genetic change may be one of 
major effect but may have reduced penetrance, explaining why there is no manifestation 
of autism in the mother or one of the sisters with the mutation. Incomplete penetrance 
appears to be the rule in psychiatric diseases, as the concordance rates for autism in 
monozygotic twins (who share a similar environment and all of their genetic material) 
varies from 40-60% and from 0-25% in dizygotic twins (who share a similar environment 
and half of their genes, on average) (1, 2, 3, 16). Finally, the phenotypic manifestations of 
the identified mutation in this family may be heterogeneous. In the example of the 
recently discovered association between idiopathic autism and mutations in NLGN4 (14) 
(see Introduction), it was later found that mutations in this gene also manifested as X- 
linked mental retardation with or without autism or PDD in a large family, suggesting 
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that some types of autistic disorder and mental retardation may have common genetic 
origins (15). In a similar manner, a closer phenotypic evaluation of this family may 
suggest that the missense mutation discovered here may co-segregate with some other 
aspect of their presentations. 
Keeping with the assumption that this T723947G mutation in CNTN4 increases 
susceptibility to ASDs in this family, it is more difficult to explain why there are three 
affected siblings (two with autism and one “NQA”) that do not carry this mutation. It 
seems more likely that other, more relevant (genetic or other) risk factors for ASD are 
shared in this family, and that the particular CNTN4 mutation detected here is of very 
little, if any, significance toward autism susceptibility. 
In addition to this genetic change within an exon of CNTN4, two different intronic 
genetic variations were observed in different patients. Although this study did not set out 
to examine intronic, or non-coding, sequence of CNTN4, the purposeful design of PCR 
primers to include sequence flanking the intron/exon boundaries, or splice sites, 
invariably included several base pairs of intron sequence. In one autistic patient, a 
heterozygous intronic variant (IVS8+13 T>G) was found (Table 3, Figure 9A). There is 
no record of this variation being reported in any online SNP databases, either because it is 
truly rare or because the SNP has yet to be recorded. Due to its distance from the exon 8 
splice site, it is unlikely that this mutation would interfere with normal transcription. 
However, it may be revealing to check for this unreported intronic variant in control 
subjects and members of the proband’s family. 
The second heterozygous intronic variant (IVS20-8 C>T) was found in 37 of 95 
AGRE patients (Table 3, Figure 9B). According to the online SNP databases, this variant 
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is common in the general population (refSNP 6800354), with an estimated (T) allele 
frequency of 0.17. Due to its relatively high prevalence and location in non-coding 
sequence, it is unlikely that this SNP contributes to autism susceptibility in any 
significant way. Such variations are relatively common in the human genome. Current 
estimates are that SNPs (by definition, having a minor allele frequency of at least 1% in 
the general population) are found at the rate of 1 in every 200-300 bp in the genome (58, 
59). While most SNPs in the human genome are found outside of coding sequence, SNPs 
found within a coding sequence are of particular interest because they are more likely to 
alter the biological function of a protein. 
Based on these initial mutation screening results for CNTN4, it would be valuable 
to complete mutation screening for all translated exons for the entire initial cohort of 
AGRE patients. With recent technological advances, screening for mutations has become 
faster and cheaper since the start of this study. As a result, it may be feasible to expand 
this initial cohort to include additional AGRE patients as well as patients with other 
phenotypic similarities to our index case (Case 1), namely patients with MR and/or non¬ 
verbal learning disability with a delay in language acquisition. 
Cases 2-4 
One male and two female siblings meeting Diagnostic and Statistical Manual of 
Mental Disorders IV (DSM-IV), as well as Autism Diagnostic Interview-Revised (ADI- 
R) and Autism Diagnostic Observation Schedule (ADOS), criteria for autistic disorder 
and their unaffected mother were found to have a balanced translocation 
V. 
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t(4;l I)(q25;pl5). One breakpoint was mapped to within a 67 kb region on chromosome 
11 p 15.4 (Figure 6B). The location of this breakpoint is approximately 13 Mb telomeric to 
a recently reported area of interest (multipoint LOD =1.72) in autism spectrum disorders 
based on a genome-wide screen of 345 families (10). The second breakpoint was mapped 
to within a 148 kb region on chromosome 4q25 (Figure 6D), mapping a considerable 
distance (28 Mb) from a region of suggestive linkage (multipoint LOD=2.24) in the same 
genome-wide scan. 
While several case reports of abnormalities involving chromosome 4q have been 
noted in the literature (60-62), none of these breakpoints overlap with or even fall within 
20 Mb of the 4q breakpoint reported here. Several association studies of candidate genes 
near our breakpoint on 11 p 15.4 may complement our evidence for a possible 
susceptibility gene at or near this locus. Herault et al. report the identification of a 
positive association between autism and a particular genotype at two different c-Harvey- 
ras (HRAS) oncogene markers located on 1 lpl5.5 (63-65). This association at one such 
marker was later replicated in a second population of autistic subjects (66). The product 
of HRAS is involved in the proliferation and differentiation of neural cells, and therefore 
could play a role in the etiology of autism (65). In addition, it is interesting to note that 
the Ras protein is an upstream regulator of the ERK MAPK signaling cascade, which is 
widely involved in CNS synaptic plasticity (67, 68). With this crucial role of Ras in one 
of the most studied pathways in learning and memory, a mutation affecting this protein 
could adversely affect important synaptic changes that occur during nonnal development 
and result in developmental delay. In fact, mutations of several genes coding for proteins 
that interact with Ras (NF1) and other proteins in the ERK pathway (RSK2, CPB) have 
' 
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been shown to cause several developmental disorders (mental retardation in 
neurofibromatosis, Coffm-Lowry Syndrome MR, and Rubinstein-Taybi Syndrome MR, 
respectively) (68-70). Yamagata et al. examined the human secretin locus (SCT), 
adjacent to HRAS at 1 lp 15.5, and found three out of 75 Caucasian and Japanese autistic 
patients who displayed unique, non-conservative coding mutations that were not present 
in controls (71). The breakpoint on 1 lp in our family is located approximately 5.9 Mb 
from these previously reported candidate genes. 
While our breakpoints fall outside of previously reported linkage peaks and 
associated candidate gene intervals, several cases have been described in which 
chromosomal abnormalities separated by large genomic distances from disease-related 
genes may still disrupt gene expression by epigenetic alterations and lead to the disease 
phenotype (57, 72, 73). Mechanisms by which this may occur include the dissociation of 
a regulatory element from a disease gene or the transposition of a gene from its usual 
chromatin environment which may result in inadequate or mistimed expression of a 
functional protein. In this manner, it is still possible that one or both of the breakpoints 
identified in this multiplex family may correlate with increased susceptibility to autism, 
even if they do not structurally disrupt a transcript. As illustrated by the few cases of X 
chromosome deletions that led to the discovery of a correlation between mutations in 
NLGN4 and autism (13, 14), studying chromosomal abnormalities, even when 
breakpoints are outside of known linkage or candidate gene intervals, can allow us to 
detect low frequency disease mutations that may not be detected via other methods. 
There is still the possibility that one of the breakpoints observed in this family 
physically disrupts a transcript within the identified breakpoint regions or disrupts a 
V. 
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regulatory region for a nearby transcript. One predicted gene identified in the interval on 
chromosome 11 (KIAA0409) is of particular interest for possible relevance toward the 
affected status of the three children in this family. This predicted gene is noted to encode 
a hypothetical protein (Cerebral protein-1) that appears to belong to a family of 
uncharacterized eukaryotic proteins which are related to methyltransferases. It is 
interesting to note that abnormalities in repressing the transcription of methylated DNA 
in brain have been shown to lead to an autism-spectrum phenotype in females. 
Specifically, mutations in the gene encoding MeCP2 have been shown to cause Rett’s 
syndrome (74, 75). MeCP2 is a protein that has been shown to be particularly abundant in 
brain, binding specifically to methylated DNA to repress transcription. Since the 
KIAA0409 protein has a putative function related to DNA methylation in brain, it is 
conceivable that a functional alteration of this gene may confer an autism phenotype by 
mechanisms similar to that described for MeCP2. Further investigation into whether this 
gene is functionally disrupted in this family and possibly mutation screening of this gene 
in ASD patients is warranted. 
The putative association between the currently reported translocation and autism in 
this family should not be dismissed merely because the mother does not show features of 
autism. One possible explanation is that the translocation is not solely responsible for the 
siblings’ autism. The genetic change resulting from the rearrangement may be 
compounded by other genetic and non-genetic factors, such as a secondary mutation, or 
environmental factors, such as exposure to pathogens or teratogens, that increase the 
likelihood of developing autism. Second, the abnormality may have reduced penetrance, 
explaining why there is no manifestation of autism in the mother. Finally, it is not 
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possible to exclude epigenetic factors as an explanation for the unaffected mother. The 
normal maternal imprinting of a genetic locus on chromosome 4 or 11 may be affected by 
the balanced chromosomal translocation such that maternal transmission of this locus 
may have dramatically increased susceptibility to autism in her offspring. A precedent for 
such a potential mechanism in has previously been implicated in psychiatry; maternal 
transmission of interstitial duplications of 15q 11-13 is the most frequent chromosomal 
abnormality in ASD (76, 77); 
In summary, the presence of three affected children with classic autism all carrying an 
identical rearrangement raises the prospect of a causal relationship in this family. This 
finding suggests that further annotation of these genomic intervals and mutation 
screening of prioritized candidate genes at these breakpoints should be undertaken. 
Conclusions 
This study has identified a gene, Contactin 4, whose haploinsufficieny appears 
sufficient to confer major aspects of the 3p deletion syndrome phenotype, including 
developmental delay. Initial mutation screening of this gene in a cohort of patients with 
autism spectrum disorders suggests that CNTN4 may have relevance in the pathogenesis 
of rare cases of autism spectrum disorders. In addition, a brain-expressed gene was 
identified near the translocation breakpoint in a multiplex autistic family that appears to 
be a good candidate for mutation screening in autism. 
As demonstrated by the cases of chromosomal rearrangements analyzed in this 
study, the investigation of genotypic outliers in complex disease such as developmental 
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neuropsychiatric disorders is a valuable and worthwhile approach toward elucidating 
genetic risk factors. This approach has shown success in identifying rare genetic variants 
conferring susceptibility to ASDs (NLGN4), a task in which more traditional approaches 
such as whole genome linkage analysis would fail. Despite being rare, these susceptibility 
variants are invaluable because they may provide insight into the underlying biology of 
the disorders and may provide unexpected clues about where to look to discover more 
common risk factors. 
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APPENDIX 
Table Al. Conditions for PCR amplification and dHPLC mutation screening of CNTN4 exons 
Exon 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24a 
24b 
24c 
24d 
24e 
24f 
DHPLC 
Forward Primer Reverse Primer Amplicon size Annealing Temp 
(5,^31)(5’-» 31) (bp)Temp (°C) (°C) 
TGCCTATGAGCAGGTCCATAC 
ACAGGTAAGCATCACCTACCC 
TTTGAGTAAAGATAAACTTGCA 
GAGAC 
TGGAAGGGATTCTTCATTTTG 
GATGTCACCATTGCTGGGTAG 
TTTGAAATAGTGGTACTCTCCCT 
TG 
TGGGCTGAAAAAGAGTCATTG 
CATTCTGCATTAACAGAAAAAT 
GAG 
ACCAAGAAGGAAGCGTTTAGG 
TGAGTACACACTGAATATACAC 
CTTTC 
TGGTAAAATTGCCTTAAAGTCTC 
AG 
ATCTCATGGAAGGCTGTCTTG 
TGAGATAAATTTCACCATTTTTG 
G 
TTTCCACAC AAGCTC ACAGAC 
CCATTAGTCACCGTGTCCTTC 
TTGAATACACTGCTCCAATTCTG 
TTCCTAACGTAATCTCTGCATTT 
G 
TTGCCGCCTGACATAACTTG 
CGATTTTTGCATTTGAGTGAAAC 
AATGCTAGTATCTACAATCCTGT 
CC 
CCTTTGTCCTGATAGCTCTGC 
GGAGATATTCCTCAGAATCCAT 
TG 
TCCATATTTGGGACCTTTGTG 
TCATTTCCAGTAGAATCCATGC 
TGCTTCTTTAGGAATGGCATTAT 
AC 
TGTAAAATGCTATGGGCAACAC 
TTGAGATGGTTTCAGGAATGG 
AAGTAATTCTCTGTCAATGGATT 
CG 
TTCTGTTTTGCAATAGGTAGCC 
TAAACATGCTGCCACCTTTTC 
CGACCCACTGCAGATATTCC 
TCTGTAAGGGAAGGTTTTCAAT 
G 
AAAGTGAAGGCCCACTTTTG 
CAGAAACTATATGCATGGAAAC 
AC 
AAAATCTAGTCTCTAAAATGAA 
ACTGC 
GGAGGGAGAACATTGAGGAAG 
TACCTCCACATTCATCCTGTG 
GAAGGGAGGATGAGAAGGAA 
CCTATTCTGCACCATCTCTCC 
GGCAATGAGGCTATATTAAACG 
TGGATTGAACATTTATGCTTGG 
AATTCCCAAATCCAGAAGGAC 
TCGGTAGATTACATTATTAGAC 
ACGAG 
TTTATTGTGCAAAAAGGAGCAG 
GTTTCTGGAACTCTGCGCTAC 
GCTGAGTTCCCAATGTCTCTG 
CAAGAATTCAAACGCTTTTCC 
CCCAGCTATGTCTAACATGGAG 
TGTACCATGCGAAATTGATTG 
CAAGGGGCATAGACTCTCTTTC 
TTGGGATATGTGTGATGAATCC 
CACTCACAGCACGATTAGGTG 
TAAGACAGGCAGGAGAAAAGG 
TGCATATAAGGACATATGTAAA 
CTGC 
TTTGCATACAACAGCCTTGAG 
AACTTTGGGTCTATGTTACTACA 
GG 
GATTC'AAAAGAAGGGCTCTATT 
ATTAC 
TTGCCTTTTATGTCACTGTCC 
GGAACACAGCTTGAAATACTGA 
C 
GGTAAGCTAACAAATTCCCTGA 
C 
234 56.0 59.0 
233 58.1 55.0 
300 56.8 52.0,57.0 
215 58.1 55.0 
439 59.1 53.0,58.0 
243 58.1 54.0,59.0 
382 59.1 57.0 
225 58.1 53.0,58.0 
375 56.8 57.0 
250 58.1 56.0 
288 58.1 56.0 
392 58.1 56.0 
241 58.1 56.0 
382 58.1 53.0,58.0 
280 58.1 58.0 
245 56.0 56.0,61.0 
294 60.0 60.0 
191 60.0 55.0,60.0 
389 58.1 55.0,60.0 
233 58.1 53.0,58.0 
380 58.1 58.0 
227 58.1 56.0 
270 58.1 59.0 
480 58.1 55.0, 60.0 
398 58.1 50.0,55.0 
500 58.1 53.0,58.0 
386 58.1 51.0,56.0 
383 58.1 53.0 
397 58.1 54.0 
458 58.1 54.0 24g 
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Table A2. Selected features of 3p deletion syndrome 
Features of 3p- syndrome Percent Affected* Present (+) or Absent (-) 
in Case 1 
Developmental Delay 86% + 
Post natal growth retardation 86% + 
Ptosis 77% + 
Low birth weight 73% - 
Malformed ears 68% + 
Long Philtrum 68% - 
Broad Nasal Bridge 64% + 
Hypotonia 50% + 
Microcephaly 50% - 
Micrognathia 50% - 
Epicanthal Folds 41% + 
Post Axial Polydactyly 40% - 
Hyperteliorism 36% + 
Feeding problems 29% + 
Clinodactyly 27% + 
Trigonocephaly 23% - 
Downtumed comers of mouth 24% + 
Synophrys 18% + 
Low Frontal Hairline 14% + 
A Frequency data is derived from the most recent and largest case review in the literature 
(43) consisting of 22 total patients 
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